Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cancer Letters

• Publication date

  2007-06-28

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.CANLET.2006.12.004PMID 17240048
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.

  2007cited by this paper
• Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

  2006cited by this paper
• Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection.

  2006cited by this paper
• Mechanism of Aurora B activation by INCENP and inhibition by hesperadin.

  2005cited by this paper
• A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

  2005cited by this paper
• Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

  2005cited by this paper
• A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

  2004cited by this paper
• VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

  2004cited by this paper
• Structural basis of Aurora-A activation by TPX2 at the mitotic spindle.

  2003cited by this paper
• The cellular geography of Aurora kinases

  2003cited by this paper
• Crystal Structure of Aurora-2, an Oncogenic Serine/Threonine Kinase*

  2002cited by this paper
• The GIST of targeted cancer therapy: A tumor (Gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571)

  2002cited by this paper
• Human TPX2 is required for targeting Aurora-A kinase to the spindle

  2002cited by this paper
• High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.

  2002cited by this paper
• Multiple hematopoietic cell lineages develop in vivo from transplanted Pax5-deficient pre-B I-cell clones.

  2002cited by this paper
• Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation

  2001cited by this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper
• Structure of GSK3β reveals a primed phosphorylation mechanism

  2001cited by this paper
• Identification of novel FLT‐3 Asp835 mutations in adult acute myeloid leukaemia

  2001cited by this paper
• Structure of GSK3beta reveals a primed phosphorylation mechanism.

  2001cited by this paper
• Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

  2000cited by this paper
• Aurora/Ipl1p-related kinases, a new oncogenic family of mitotic serine-threonine kinases.

  1999cited by this paper
• The biology of chronic myeloid leukemia.

  1999cited by this paper
• The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis.

  1999cited by this paper
• A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase

  1998cited by this paper
• Recent developments for the efficient crystallographic refinement of macromolecular structures.

  1998cited by this paper
• A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers

  1998cited by this paper
• Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

  1996cited by this paper
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  1996cited by this paper
• The CCP4 suite: programs for protein crystallography.

  1994cited by this paper
• Phosphotransferase and substrate binding mechanism of the cAMP‐dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 A structure of the complex with Mn2+ adenylyl imidodiphosphate and inhibitor peptide PKI(5‐24).

  1993cited by this paper
• The protein kinase family: conserved features and deduced phylogeny of the catalytic domains.

  1988cited by this paper

• Primary cilia in cancer: structures, functions, mechanisms, and therapeutic implications

  2025cites this paper
• Drug Metabolism: Other Phase I Enzymes

  2021cites this paper
• Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy

  2021cites this paper
• Computer aided designing of novel pyrrolopyridine derivatives as JAK1 inhibitors

  2021cites this paper
• Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells

  2021influential citation
• Ponatinib, Lestaurtinib, and mTOR/PI3K Inhibitors Are Promising Repurposing Candidates against Entamoeba histolytica

  2021cites this paper
• Aurora kinase inhibitor tozasertib suppresses mast cell activation in vitro and in vivo

  2020cites this paper
• Structure-Based Discovery and Bioactivity Evaluation of Novel Aurora-A Kinase Inhibitors as Anticancer Agents via Docking-Based Comparative Intermolecular Contacts Analysis (dbCICA)

  2020cites this paper
• Inhibitor binding to mutants of protein kinase A with GGGxxG and GxGxxA glycine‐rich loop motifs

  2020cites this paper
• Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4.

  2019cites this paper
• Aurora kinase inhibitor VX‑680 suppresses the proliferation and migration of HUVECs and angiogenesis.

  2019cites this paper
• Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors

  2019cites this paper
• Novel combination strategies with Aurora Kinase Inhibitors : using pre-clinical data to guide clinical trial design

  2019influential citation
• Successful treatment of a chronic-phase T-315 I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon

  2018cites this paper
• LY2874455 potently inhibits FGFR gatekeeper mutants and overcomes mutation-based resistance.

  2018cites this paper
• Molecular biology as a tool for the treatment of cancer

  2018cites this paper
• RIPK1-dependent cell death: a novel target of the Aurora kinase inhibitor Tozasertib (VX-680)

  2018cites this paper
• Cell Proliferation and Differentiation

  2017cites this paper
• Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation

  2016cites this paper
• Kinase inhibitors as potential agents in the treatment of multiple myeloma

  2016cites this paper
• Tyrosine Kinase Inhibitors in Ph+ Chronic Myeloid Leukemia Therapy: a Review.

  2016cites this paper
• Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress.

  2015cites this paper
• Structural Biology Insight for the Design of Sub-type Selective Aurora Kinase Inhibitors.

  2015cites this paper
• PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.

  2014cites this paper
• Spindle Assembly Checkpoint (SAC): More New Targets for Anti-Cancer Drug Therapies

  2014cites this paper
• 2-tert-butyl-1,4-benzoquinone Induces Apoptosis in Chronic MyeloidLeukemia Cells Resistant to Imatinib via Inducing Caspase-Dependent Bcr-Abl Downregulation

  2014cites this paper
• Discovery of 4-aminoquinazoline--urea derivatives as Aurora kinase inhibitors with antiproliferative activity.

  2014cites this paper
• HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.

  2014cites this paper
• 2-tert-butyl-1,4-benzoquinone Induces Apoptosis in Chronic Myeloid Leukemia Cells Resistant to Imatinib via Inducing Caspase-Dependent Bcr-

  2014cites this paper
• Identification of new novel scaffold for Aurora A inhibition by pharmacophore modeling and virtual screening

  2014cites this paper
• Identification of Aurora‐A Inhibitors by Ligand and Structure‐Based Virtual Screening

  2014cites this paper
• Discovery of 7‐Aryl‐Substituted (1,5‐Naphthyridin‐4‐yl)ureas as Aurora Kinase Inhibitors

  2014cites this paper
• A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

  2014cites this paper
• Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity.

  2013cites this paper
• MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia

  2013cites this paper
• Hydrosoluble Benzo[e]pyridoindolones as Potent Inhibitors of Aurora Kinases

  2013cites this paper
• Basal aurora kinase B activity is sufficient for histone H3 phosphorylation in prophase

  2013cites this paper
• Design, synthesis, quantum chemical studies and biological activity evaluation of pyrazole-benzimidazole derivatives as potent Aurora A/B kinase inhibitors.

  2013cites this paper
• Targeting the cancer initiating cell: the ultimate target for cancer therapy.

  2012cites this paper
• Crystal Structure of Human Aurora B in Complex with INCENP and VX-680

  2012cites this paper
• Emerging Pharmacotherapies for Adult Patients with Acute Lymphoblastic Leukemia

  2012cites this paper
• Aurora kinase inhibitors: Progress towards the clinic

  2012cites this paper
• Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa

  2012cites this paper
• Emerging therapies in chronic myeloid leukemia.

  2012cites this paper
• New Kinase Inhibitors for the Treatment of Chronic Hematological Neoplasms-Editorial

  2012cites this paper
• Bioinformatics and variability in drug response: a protein structural perspective

  2012cites this paper
• Synthesis and Biological Evaluation of Novel N-Methyl-picolinamide-4-thiol Derivatives as Potential Antitumor Agents

  2012cites this paper
• Biology of Aurora A kinase: Implications in cancer manifestation and therapy

  2011cites this paper
• Discovery and Design of Protein Kinase Inhibitors: Targeting the Cell Cycle in Oncology

  2011cites this paper
• Oleic acid is the active component in the mushroom Daedalea gibbosa inhibiting Bcr-Abl kinase autophosphorylation activity.

  2011cites this paper
• Inhibition of proliferation, viability, migration and invasion of gastric cancer cells by Aurora-A deletion.

  2011cites this paper
• Current status of agents active against the T315I chronic myeloid leukemia phenotype

  2011cites this paper
• Update on aurora kinase targeted therapeutics in oncology

  2011influential citation
• Computational approach to the identification of novel Aurora-A inhibitors.

  2011cites this paper
• VX680 binding in Aurora A: π-π interactions involving the conserved aromatic amino acid of the flexible glycine-rich loop.

  2011cites this paper
• NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells.

  2011cites this paper
• New insights into small‐molecule inhibitors of Bcr‐Abl

  2011cites this paper
• Mutants of protein kinase A that mimic the ATP-binding site of Aurora kinase.

  2011cites this paper
• Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib

  2011cites this paper
• Impact of BCR-ABL mutations on patients with chronic myeloid leukemia

  2011cites this paper
• BCR ABL KINASE INHIBITORS FOR CANCER THERAPY

  2010cites this paper
• Investigation into the role of Aurora A kinase activity during mitosis

  2010cites this paper
• Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia.

  2010cites this paper
• Identification, SAR Studies, and X‐ray Co‐crystallographic Analysis of a Novel Furanopyrimidine Aurora Kinase A Inhibitor

  2010cites this paper
• New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms.

  2010cites this paper
• Discovery of pyrrole-indoline-2-ones as Aurora kinase inhibitors with a different inhibition profile.

  2010cites this paper
• Natural products in structure-assisted design of molecular cancer therapeutics.

  2010cites this paper
• Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors.

  2010cites this paper
• 3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: selective Aurora A kinase inhibitors.

  2010cites this paper
• Discovery and Exploitation of Inhibitor-resistant Aurora and Polo Kinase Mutants for the Analysis of Mitotic Networks◆

  2009cites this paper
• The discovery of the potent aurora inhibitor MK-0457 (VX-680).

  2009cites this paper
• Small molecule aurora kinases inhibitors.

  2009cites this paper
• Cancer driver mutations in protein kinase genes.

  2009cites this paper
• N-substituted 2'-(aminoaryl)benzothiazoles as kinase inhibitors: hit identification and scaffold hopping.

  2009cites this paper
• Safety, pharmacokinetics and pharmacodynamics of targeted anti-cancer drugs

  2009cites this paper
• Triptolide Inhibits Bcr-AblTranscription and Induces Apoptosis in STI 571-resistant Chronic Myelogenous Leukemia Cells

  2009cites this paper
• Advances in Aurora kinase inhibitor patents

  2009cites this paper
• Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity.

  2009cites this paper
• Triptolide Inhibits Bcr-Abl Transcription and Induces Apoptosis in STI571-resistant Chronic Myelogenous Leukemia Cells Harboring T315I Mutation

  2009cites this paper
• Benzo[e]pyridoindoles, novel inhibitors of the Aurora kinases

  2009cites this paper
• An intracellular conformational sensor assay for Abl T315I.

  2009cites this paper
• Structural biology contributions to tyrosine kinase drug discovery.

  2009cites this paper
• Mechanism of MK-0457 efficacy against BCR-ABL positive leukemia cells.

  2009cites this paper
• Les inhibiteurs des kinases Aurora

  2009cites this paper
• Clinical experience with aurora kinase inhibitors: a review.

  2009cites this paper
• Discovery and development of aurora kinase inhibitors as anticancer agents.

  2009cites this paper
• [Inhibitors of aurora kinases].

  2009cites this paper
• Targeting the leukemic stem cell: the Holy Grail of leukemia therapy

  2009cites this paper
• Aurora A Is Essential for Early Embryonic Development and Tumor Suppression*

  2008cites this paper
• Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia

  2008cites this paper
• Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression

  2008cites this paper
• Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia.

  2008cites this paper
• Cotreatment with Vorinostat Enhances Activity of MK-0457 (VX-680) against Acute and Chronic Myelogenous Leukemia Cells

  2008cites this paper
• Modulation of kinase‐inhibitor interactions by auxiliary protein binding: Crystallography studies on Aurora A interactions with VX‐680 and with TPX2

  2008influential citation
• Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

  2008cites this paper
• Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)

  2008cites this paper
• Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines.

  2008cites this paper
• Targeted drugs in chronic myeloid leukemia.

  2008cites this paper
• Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors

  2008cites this paper
• Abl tyrosine kinase inhibitors for overriding Bcr–Abl/T315I: from the second to third generation

  2008cites this paper